IFNB1 and myeloid sarcoma: Although type I interferon responses and their regulation are widely described in autoimmune diseases, including MS, the presence and action of the sIFNAR2 has not been explored, despite its ability of binding endogenous and exogenous IFN-β and modulating their activity (20–22).